EuroGuiDerm Evidence-based Guideline for the Treatment of Acne - long version

Oct 6, 2026

Uploaded by Ivy

EuroGuiDerm Evidence-based Guideline for the Treatment of Acne – long version (ICD L70.0, L70.1) provides an updated 2025 evidence-based framework for clinical management. The guideline covers objectives, target population, pharmacoeconomic and vehicle considerations for topical therapy, and clinical features across acne variants. It details assessment and comparability of outcomes, including acne grading and prognostic factors affecting treatment choice, while addressing epidemiology and pathophysiology. It also specifies methods for assessing evidence, including risk of bias and methodological quality.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages90

Reading Time3 h 47 min

AccessFree to download

Disclaimer

Introduction

Objectives of the guideline

Target population

Pharmacoeconomic considerations

Considerations with respect to vehicle for topical treatments

Considerations regarding area of involvement

Clinical features and variants

Comedonal acne

Papulopustular acne

Nodular/ conglobate acne

Other acne variants

Assessment, comparability of treatment outcomes

Acne grading

Acne grading systems

Prognostic factors that should influence treatment choice

Prognostic factors of disease severity

Influence of scarring assessment on disease management

Epidemiology and pathophysiology

Epidemiology

Pathophysiology

Methods-Assessment of evidence

Risk of bias and methodological quality (update 2025)

EuroGuiDerm Evidence-based Guideline for the Treatment of Acne – long version (ICD L70.0, L70.1) Update 2025 Long version Expiry date: June 2030 A. Nast 1 , B. Al Wattar2,3 , M. Beylot Barry4 , H. Brüggemann5 , Z. Bukvić Mokos6 , D. M. Caruana7 , K. Degitz8 , C. Dessinioti9 , B. Dréno 10 , R.J. B Driessen 11 , H. Gollnick 12 , M. Hædersdal13 , A. Katoulis 14 , S. Läuchli15 , J. Lambert 16 , A. M. Layton17,18 , G. Micali 19 , F. Ochsendorf20 , T. Sathyapalan21 , K.Z. Stangeland22 , S. F. Thomsen23 , D. Töröcsik24 , A. Pennitz1 1 Division of Evidence-Based Medicine, Klinik für Dermatologie, Charité - Universitätsmedizin Berlin, Berlin, Germany 2 Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK. 3 Beginnings Assisted Conception Unit, Epsom and St Helier University Hospitals, London, UK. 4 Dermatology Department, CHU Bordeaux, Bordeaux, France, Université de Bordeaux, Bordeaux, France 5 Department of Biomedicine, Aarhus University, 8000 Aarhus Centrum, Denmark 6 Department of Dermatology and Venereology, University Hospital Centre Zagreb, University of Zagreb School of Medicine , Zagreb, Croatia 7 Private practice, Malta 8 Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany 9 Department of Dermatology, University of Athens, Andreas Sygros Hospital , Greece 10 Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001 . F-44000 Nantes, France 11 Department of Dermatology , Radboud university medical center, Nijmegen, The Netherlands 12 Department of Dermatology and Venereology, University of Magdeburg, Magdeburg, Germany 13 Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark 14 Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece 15 Institute of Dermatology and Venerology, Stadtspital Zürich 16 Department of Dermatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium 17 Skin Research Centre, Hull York Medical School, University of York, UK 18 Department of Dermatology, Harrogate and District NHS Trust, Harrogate, UK 19 Department of Dermatology, University of Catania, Sicily, Italy 20 Goethe-University Frankfurt, Universitätsmedizin, Department of Dermatology, Venereology and Allergology, Frankfurt, Germany 21 Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK 22 Department of Dermatology and Venereology, Aleris Stavanger, Stavanger, Norway 23 Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark 24 Department of Dermatology, Faculty of Medicine, University of Debrecen and ELKH-DE Allergology Research Group, Debrecen, Hungary Table of contents EuroGuiDerm Evidence-based........................................................................ II Guideline for the Treatment of Acne – long version ..................................... II 1 Disclaimer .................................................................................................. 1 2 Introduction ............................................................................................... 3 2.1 Objectives of the guideline ............................................................................................. 3 2.2 Target population............................................................................................................ 5 2.3 Pharmacoeconomic considerations ............................................................................... 5 2.4 Considerations with respect to vehicle for topical treatments ........................................ 6 2.5 Considerations regarding area of involvement........................................

FAQs

What topics does the EuroGuiDerm acne guideline cover in this long version?

It covers guideline objectives and target population, pharmacoeconomic and topical vehicle considerations, clinical features across acne variants, and factors influencing treatment choice. It also includes outcome assessment methods, epidemiology/pathophysiology, and evidence-assessment methodology with risk of bias.

How does the guideline suggest assessing acne severity and prognosis?

It addresses acne grading systems and highlights prognostic factors that should influence treatment choice, including factors related to disease severity and how assessment of scarring potential informs disease management.

What evidence-assessment approach is described?

The guideline specifies methods for assessing evidence, including evaluation of risk of bias and methodological quality, with an update noted for 2025.

Oct 6, 2026

Uploaded by Ivy